Biblio Discovery — Demo Discovery Service

38 hasil untuk "Jaume Capdevila"

Menampilkan 1–20 · 1,65 detik · RSS

  1. Artikel Jurnal

    What is the status of immunotherapy in thyroid neoplasms?

    Alejandro Garcia-Alvarez; Jorge Hernando; Ana Carmona-Alonso dkk.

    Frontiers in Endocrinology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive biomarkers of response and efficacy of immunotherapy…

  2. Artikel Jurnal

    A significant response to sunitinib in a patient with anaplastic thyroid carcinoma

    Enrique Grande; Jaume Capdevila; Juan José Díez dkk.

    Journal of Research in Medical Sciences, Vol. 18 No. 7 · 2013 · Inggris · DOAJ Scopus

    Anaplastic thyroid cancer (ATC) is a rare disease with an incidence of less than three cases per million of habitants in western countries. ATC accounts for 1-10% of all tumors derived from the thyroid gland. Classic chemotherapy approach based on platinum and anthracyclines regimens have been…

  3. Artikel Jurnal

    Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe

    Rossella Elisei; Enrique Grande; Michael C. Kreissl dkk.

    Frontiers in Oncology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    The incidence of thyroid cancer is increasing worldwide with the disease burden in Europe second only to that in Asia. In the last several decades, molecular pathways central to the pathogenesis of thyroid cancer have revealed a spectrum of targetable kinases/kinase receptors and oncogenic drivers…

  4. Artikel Jurnal

    Cabozantinib for the treatment of solid tumors: a systematic review

    Pablo Maroto; Camillo Porta; Jaume Capdevila dkk.

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · Inggris · DOAJ Scopus

    Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib…

  5. Artikel Jurnal

    Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

    Daniel Castellano; Andrea B. Apolo; Camillo Porta dkk.

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · Inggris · DOAJ Scopus

    Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy…

  6. Artikel Jurnal

    Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor

    Jesús Yaringaño; Jorge Hernando; Alejandro García-Álvarez dkk.

    Frontiers in Oncology, Vol. 16 · 2026 · Inggris · DOAJ Scopus

    ALK rearrangements are rare but actionable oncogenic drivers in thyroid cancer, particularly in aggressive histologies such as poorly differentiated thyroid carcinoma (PDTC), and evidence supporting sequential ALK inhibition in this setting is scarce. We report a 19-year-old male with…

  7. Artikel Jurnal

    Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

    Oriol Mirallas; Francesca Filippi-Arriaga; Irene Hernandez Hernandez dkk.

    Frontiers in Endocrinology, Vol. 12 · 2021 · Inggris · DOAJ Scopus

    Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can…

  8. Artikel Jurnal Teks lengkap

    SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)

    Castillón, Jaume Capdevila; Gordoa, Teresa Alonso; Bayonas, Alberto Carmona dkk.

    Clin Transl Oncol · 2023 · Inggris · PubMed Central

    Neuroendocrine neoplasms (NENs) are a heterogeneous family of tumors of challenging diagnosis and clinical management. Their incidence and prevalence continue to rise mainly due to an improvement on diagnostic techniques and awareness. Earlier detection, along with steadfast improvements in…

  9. Artikel Jurnal

    Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

    Simron Singh; Diego Ferone; Jaume Capdevila dkk.

    Trials, Vol. 25 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Background The current standard of care (SoC) for the initial treatment of unresectable or metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) requires initiation of first-generation somatostatin receptor ligand (SRL) therapy, octreotide and lanreotide…

  10. Artikel Jurnal

    Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

    Jaume Capdevila; Desiree’ Deandreis; Cosimo Durante dkk.

    European Thyroid Journal, Vol. 12 No. 5 · 2023 · Inggris · DOAJ Scopus

    Background: Most thyroid cancers of follicular origin have a favorable outcome. Only a small percentage of patients will develop metastatic disease, some of which will become radioiodine refractory (RAI-R). Important challenges to ensure the best therapeutic outcomes include proper, timely, and…

  11. Artikel Jurnal

    Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review

    Enrique Grande; Ángel Díaz; Carlos López dkk.

    Therapeutic Advances in Endocrinology and Metabolism, Vol. 10 · 2019 · Inggris · DOAJ Scopus

    Background: Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses…

  12. Artikel Jurnal

    Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

    Marta Benavent; Javier Sastre; Ignacio García Escobar dkk.

    Health and Quality of Life Outcomes, Vol. 19 No. 1 · 2021 · Inggris · DOAJ Scopus

    Abstract Background and objective Patient-reported outcome measures can provide clinicians with valuable information to improve doctor-patient communication and inform clinical decision-making. The aim of this study was to evaluate the physician-perceived utility of the QLQ-GINET21 in routine…

  13. Artikel Jurnal

    Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus

    Aleš Ryška; Jaume Capdevila; Matthias S Dettmer dkk.

    European Thyroid Journal, Vol. 14 No. 4 · 2025 · Inggris · DOAJ Scopus

    As new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely biomarker testing is crucial for treatment selection and requires a multidisciplinary approach. Recently published European guidelines on advanced/metastatic TC management…

  14. Artikel Jurnal Teks lengkap

    Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

    Esmée A. Dijkstra; Per J. Nilsson; Geke A.P. Hospers dkk.

    Annals of Surgery · 2023 · Inggris · OpenAlex Scopus

    OBJECTIVE: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. BACKGROUND: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3…

  15. Artikel Jurnal Teks lengkap

    PD-1 Blockade in Anaplastic Thyroid Carcinoma

    Jaume Capdevila; Lori J. Wirth; Thomas Ernst dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid…

  16. Artikel Jurnal

    Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

    Marcia S. Brose; Bhumsuk Keam; Jolanta Krajewska dkk.

    Frontiers in Oncology, Vol. 16 · 2026 · Inggris · DOAJ Scopus

    BackgroundCabozantinib is approved for previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) based on improved progression-free survival (PFS) versus placebo in the COSMIC-311 study. The BRAFV600E mutation is common in DTC and is associated with poor prognosis. This…

  17. Artikel Jurnal

    A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

    Maria Balaguer-Montero; Adrià Marcos Morales; Marta Ligero dkk.

    Cell Reports Medicine, Vol. 6 No. 4 · 2025 · Inggris · DOAJ Scopus

    Summary: Liver tumors, whether primary or metastatic, significantly impact the outcomes of patients with cancer. Accurate identification and quantification are crucial for effective patient management, including precise diagnosis, prognosis, and therapy evaluation. We present SALSA (system for…